Chest Infections
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
From decline to resurgence: Rise and response to US and global TB burden
TB prevalence has been rising since 2019, driven by reduced precautions and conflicts, though shorter treatments and strategic plans offer hope for elimination.
-
Supporting vaccinations in the name of public health
CHEST supports the fundamental responsibility of a public health system to seek out and apply evidence-based medicine in the development of sound policies essential to preventing illness.
-
Mitigating risk of asthma emergencies during respiratory season
During flu season, asthma emergencies become a heightened concern, especially among children. Proactive measures including vaccination, updated asthma action plans, and access to quick relief medications are critical.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all […]
-
Bronchiectasis: A call to action
Bronchiectasis is an extremely heterogeneous airways disease, making it difficult to study. For years, the noncystic fibrosis (CF) bronchiectasis community has been trying to organize to provide better care for […]
-
Trauma epidemiology and the organization of trauma care in the US
Patients who are injured do better when treated at trauma centers. During CHEST 2023 in Honolulu last year, the Disaster Response and Global Health Section hosted a presentation to a […]
-
Fellow to use diversity scholar mentorship to strengthen care in pediatric-to-adult transitions
During residency training at the Rush University Medical Center in Internal Medicine and Pediatrics, Esha Kapania, MD, quickly became interested in the pulmonary pathologies that span the life of a […]
-
Can VAP be prevented? New data suggest so
Ventilator-associated pneumonia (VAP) is a common cause of hospital-related morbidity in critically ill patients. The efficacy of prophylactic antibiotics in the prevention of VAP has been the subject of several […]
-
Eradicating uncertainty: A review of Pseudomonas aeruginosa eradication in bronchiectasis
Bronchiectasis patients have dilated airways that are often colonized with bacteria, resulting in a vicious cycle of airway inflammation and progressive dilation. Pseudomonas aeruginosa is a frequent airway colonizer and […]
-
Management of severe respiratory viruses in 2024
Viral infections frequently cause acute respiratory failure requiring ICU admission. In the United States, influenza causes over 50,000 deaths annually and SARS-CoV2 resulted in 170,000 hospitalizations in December 2023 alone.1 […]
-
Update on seasonal flu, RSV infections, and vaccines
November 12 marks World Pneumonia Day, and while it has long been recognized that viruses play a significant role in causing pneumonia, awareness has surged due to the COVID-19 pandemic. […]